Mark Boguniewicz

7PUBLICATIONS
41CO-AUTHORS
Environmental epidemiologyInfant and child healthAdolescent healthPsychology of ageingAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 02, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.

Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati

|Feb 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.

Lawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati

|Nov 15, 2024
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies.

Eric L Simpson, Matthias Augustin, Diamant Thaçi

|Oct 29, 2024
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

Mark Boguniewicz, Lawrence D Sher, Amy S Paller

|Oct 21, 2022
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.

Jonathan I Silverberg, Mark Boguniewicz, Jon Hanifin

|Jul 11, 2022
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis.

Evgeny Berdyshev, Elena Goleva, Robert Bissonnette

Pageof 2

Frequent Collaborators

3 joint publications

Jonathan I Silverberg

3 joint publications

Erin Almaraz

2 joint publications

Vimal H Prajapati

2 joint publications

Kim A Papp